Stem-cell dose for allogeneic hematopoietic stem cell transplantation in hematological malignancies: is more better?
Shimoni
Avichai
A
The Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel. ashimoni@sheba.health.gov.il
Nagler
Arnon
A
D018952:Antigens, CD34 / Q000378:metabolism; D002452:Cell Count; D006086:Graft vs Host Disease / Q000209:etiology; D020350:Graft vs Tumor Effect / Q000502:physiology; D019337:Hematologic Neoplasms / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000378:metabolism; D006801:Humans; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods; D014184:Transplantation, Homologous
D018952:Antigens, CD34